Carlton Cauthen, MD
Pulmonary Disease · Columbia, SCNPI 1346258746
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,207 of the $16,533 with a category attached, or 67.8%. 41 manufacturers reported payments, led by Sanofi at 27.0% of the total. Reporting peaked in 2019 at $5,044 and has fallen 87.7% since, to $621 in 2025.
Across 597 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- United Therapeutics Corporation$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- GSK$1K
- Actelion Pharmaceuticals US, Inc.$1K
- plus $5K from 35 others
Across 4 payments — averaging $2730.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$5K
- Actelion Pharmaceuticals, Ltd$3K
- Genentech, Inc.$3K
What the payments were for
- Consulting fees$3,67222%
- Speaking & faculty fees$1,3658%
- Travel & lodging$1331%
- Food & beverage$11,20768%
- Education$1201%
- Entertainment$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,533 in reported general payments places this provider in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 100 | $2,209,199 |
| OpsumitMacitentan | 158 | $2,015,944 |
| Orenitram ErTreprostinil Diolamine | 55 | $1,897,233 |
| OfevNintedanib Esylate | 92 | $1,282,844 |
| AdempasRiociguat | 74 | $1,017,971 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 517 | $474,523 |
| Ambrisentan | 69 | $375,128 |
| Dupixent PenDupilumab | 71 | $269,769 |
| Tadalafil | 248 | $257,226 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 217 | $168,583 |
| Breo ElliptaFluticasone/Vilanterol | 171 | $95,053 |
| Pirfenidone | 41 | $93,658 |
| Spiriva RespimatTiotropium Bromide | 127 | $91,275 |
| Fasenra PenBenralizumab | 16 | $82,747 |
| Dupixent SyringeDupilumab | 15 | $74,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,098 | $4,225,144258 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,350 | $1,442,474313 claims |
| BayerAdempas | $165 | $1,017,97174 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,127 | $612,175790 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,557 | $219,763361 claims |
| MerckDulera | $211 | $32,59577 claims |
| PfizerEliquis | $29 | $22,31724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Columbia
- Richard BoganColumbia$1.1M
- Laura HerpelColumbia$254K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
- Karla Cruz MorelColumbia$74K
- Gregory FeldmanColumbia$73K
- Liang ZhaColumbia$10K
- Todd GandyColumbia$10K
- Matthew VarnerColumbia$9K
- Abhijit RavalAnderson$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.